Loading...
•
Sep 30, 2020
Immunome Q3 2020 Earnings Report
Immunome reported third quarter 2020 financial results and significant progress.
Key Takeaways
Immunome reported a net loss of $8.4 million, or $7.52 per share, for the quarter ended September 30, 2020. The company completed an IPO in October, resulting in net proceeds of $41.7 million.
Completed $44.9M IPO in October.
Identified COVID 19 Neutralizing antibodies.
Made significant progress on lead programs, including IMM-BCP-01 for the treatment of COVID-19 in collaboration with US Department of Defense.
Awarded a $13.3 million contract from the US Department of Defense to develop an antibody cocktail.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...